Once-daily, oral chelation with deferasirox (Exjade®, ICL670) provides sustained protection from labile plasma iron in 2-thalassemia patients

被引：0
|
作者：
Daar, S.
Taher, A.
Pathare, A.
Nick, H.
Krahn, U.
Hadler, D.
机构：
[1] Sultan Qaboos Univ, Muscat, Oman
[2] Amer Univ Beirut, Beirut, Lebanon
[3] Novartis, Basel, Switzerland
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2007年 / 82卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：513 / 514
页数：2
相关论文
共 43 条
  • [21] Deferasirox (Exjade, ICL670) efficiently removes labile plasma iron as compared to desferioxamine and deferiprone: A 24-hour monitoring study in thalassemia major patients
    Zanninelli, G.
    Sorrentino, F.
    Iazzoni, R.
    Marzano, R.
    Breuer, W.
    Cabantchik, Z. I.
    Cianciulli, P.
    AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (06) : 536 - 537
  • [22] Impact on iron removal of dose reduction for non-progressive serum creatinine increases during treatment with the once-daily, oral iron chelator deferasirox (Exjade®, ICL670).
    Gattermann, N.
    Zoumbos, N.
    Angelucci, E.
    Drelichman, G.
    Siegel, J.
    Glimm, E.
    Alberti, D.
    BLOOD, 2006, 108 (11) : 32B - 32B
  • [23] A phase II study with ICL670 (Exjade®), a once-daily oral iron chelator, in patients with various transfusion-dependent anemias and iron overload
    Porter, J
    Vichinsky, E
    Rose, C
    Piga, A
    Olivieri, N
    Gattermann, N
    Maertens, J
    Rabault, B
    Gathmann, I
    Alberti, D
    BLOOD, 2004, 104 (11) : 872A - 872A
  • [24] Impact of dose adjustments on serum ferritin (SF) levels during long-term treatment with once-daily, oral deferasirox (Exjade®, ICL670)
    Porter, John B.
    Cohen, Alan R.
    Ford, John M.
    Cappellini, Maria Domenica
    BLOOD, 2007, 110 (11) : 816A - 817A
  • [25] Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis.
    Angelucci, E
    Turlin, B
    Canatan, D
    Mangiagli, A
    De Sanctis, V
    Meddeb, B
    Rose, C
    Soulieres, D
    Cunningham, M
    Gattermann, N
    Ressayre-Djaffer, C
    Rabault, B
    Ford, J
    BLOOD, 2005, 106 (11) : 757A - 758A
  • [26] IRON CHELATION THERAPY WITH DEFERASIROX (ICL670) REDUCES SERUM FERRITIN (SF) AND LABILE PLASMA IRON (LPI) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
    List, A. F.
    Baer, M. R.
    Steensma, D.
    Raza, A.
    Esposito, J.
    Virkus, J.
    Feigert, J.
    Besa, E.
    Paley, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 91 - 92
  • [27] Deferasirox (Exjade®, ICL670) treatment of inadequately chelated β-thalassemia patients from the Middle East:: The ESCALATOR trial.
    Taher, A
    El-Beshlawy, A
    Al Jefri, A
    El Alfy, M
    Al Zir, K
    Daar, S
    Al-Damanhouri, G
    Hadler, D
    Krahn, U
    BLOOD, 2005, 106 (11) : 40B - 41B
  • [28] Comparison of LIC obtained from biopsy, BLS and R2-MRI in iron overloaded patients with β-thalassemia, treated with deferasirox (Exjade®, ICL670)
    Piga, A
    Fischer, R
    Harmatz, P
    St Pierre, TG
    Longo, F
    Fung, E
    Engelhardt, R
    Perrotta, S
    Galanello, R
    Capra, M
    Vichinsky, E
    Janka-Schaub, G
    Masera, G
    Cianciulli, P
    Coates, T
    Janssen, G
    Jeng, M
    Lai, ME
    Salles, G
    Cole, P
    Alberti, D
    Rosenkranz, G
    Opitz, H
    BLOOD, 2005, 106 (11) : 755A - 755A
  • [29] Long-term treatment with the once-daily oral iron chelator deferasirox (Exjadereg], ICL670) is effective and generally well tolerated in pediatric patients.
    Piga, A.
    Bejaoui, M.
    Kiline, Y.
    Perrotta, S.
    Vichinsky, E.
    Arrowsmith-Bensasson, C.
    Glimm, E.
    Alberti, D.
    Piga, Antonio
    BLOOD, 2006, 108 (11) : 506A - 506A
  • [30] Cost-effectiveness analysis of oral iron chelation therapy with deferasirox (Exjade®, ICL670) versus infusional chelation therapy with deferoxamine in patients with transfusion-dependent myelodysplastic
    Delea, TE
    Thomas, SK
    Baladi, JF
    Phatak, PD
    BLOOD, 2005, 106 (11) : 484B - 485B
12345